Patents by Inventor Russell Dahl

Russell Dahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11890279
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Grant
    Filed: May 19, 2023
    Date of Patent: February 6, 2024
    Assignee: Neurodon Corporation
    Inventor: Russell Dahl
  • Publication number: 20240016793
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Application
    Filed: August 2, 2023
    Publication date: January 18, 2024
    Inventor: Russell Dahl
  • Patent number: 11827626
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: November 28, 2023
    Assignee: NEURODON CORPORATION
    Inventor: Russell Dahl
  • Publication number: 20230343889
    Abstract: Methods and systems are provided for photodetectors employing a hybrid PIN or PN Lead Selenium (PbSe) junction. In some examples, the PbSe junction can include one or more semiconducting layers, including n-type layers, n+-type layers, p(i)-type layers, and/or p+-type layers, as a list of non-limiting examples. Photodetectors employing PbSe PIN or PN junctions are created. Also disclosed are methods for preparing photo-sensitive PbSe semiconducting layers for detection of electromagnetic energy (e.g., mid-wavelength infrared (MWIR)).
    Type: Application
    Filed: April 14, 2023
    Publication date: October 26, 2023
    Inventors: Richard S. Kim, Jeung Hun Park, Russell Dahl
  • Publication number: 20230285382
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Application
    Filed: May 19, 2023
    Publication date: September 14, 2023
    Inventor: Russell Dahl
  • Patent number: 11730729
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: August 22, 2023
    Assignee: Neurodon Corporation
    Inventor: Russell Dahl
  • Publication number: 20220048898
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Application
    Filed: August 13, 2021
    Publication date: February 17, 2022
    Inventor: Russell Dahl
  • Publication number: 20220016108
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Application
    Filed: August 13, 2021
    Publication date: January 20, 2022
    Inventor: Russell Dahl
  • Patent number: 11220498
    Abstract: Disclosed herein are methods and compositions comprising compounds capable of activating and increasing protein SUMOylation. Disclosed herein are methods and compositions comprising compounds capable of showing neuroprotective and cytoprotective effects when administered to injured cells. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, chronic traumatic encepholopathy, traumatic brain injury, or stroke.
    Type: Grant
    Filed: December 1, 2019
    Date of Patent: January 11, 2022
    Inventor: Russell Dahl
  • Patent number: 11213701
    Abstract: Disclosed herein are methods and compositions comprising compounds capable of activating and increasing protein SUMOylation. Disclosed herein are methods and compositions comprising compounds capable of showing neuroprotective and cytoprotective effects when administered to injured cells. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, chronic traumatic encepholopathy, traumatic brain injury, or stroke.
    Type: Grant
    Filed: December 1, 2019
    Date of Patent: January 4, 2022
    Inventor: Russell Dahl
  • Publication number: 20210323924
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Application
    Filed: May 20, 2021
    Publication date: October 21, 2021
    Inventor: Russell Dahl
  • Publication number: 20210269404
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Application
    Filed: May 20, 2021
    Publication date: September 2, 2021
    Inventor: Russell Dahl
  • Publication number: 20200347038
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Application
    Filed: July 20, 2020
    Publication date: November 5, 2020
    Inventor: Russell Dahl
  • Patent number: 10800766
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: October 13, 2020
    Inventor: Russell Dahl
  • Patent number: 10793558
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: October 6, 2020
    Inventor: Russell Dahl
  • Patent number: 10772881
    Abstract: Provided herein are quinolines, e.g., a compound of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes. Also provided herein are methods of their use for modulating the activity of a sarcoplasmic/endoplasmic reticulum C2+ ATPase.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: September 15, 2020
    Inventor: Russell Dahl
  • Patent number: 10730843
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: August 4, 2020
    Inventor: Russell Dahl
  • Patent number: 10730839
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: August 4, 2020
    Inventor: Russell Dahl
  • Publication number: 20200188706
    Abstract: Disclosed herein are methods and compositions comprising compounds capable of activating and increasing protein SUMOylation. Disclosed herein are methods and compositions comprising compounds capable of showing neuroprotective and cytoprotective effects when administered to injured cells. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, chronic traumatic encepholopathy, traumatic brain injury, or stroke.
    Type: Application
    Filed: December 1, 2019
    Publication date: June 18, 2020
    Inventor: Russell Dahl
  • Publication number: 20200190078
    Abstract: Disclosed herein are methods and compositions comprising compounds capable of activating and increasing protein SUMOylation. Disclosed herein are methods and compositions comprising compounds capable of showing neuroprotective and cytoprotective effects when administered to injured cells. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, chronic traumatic encepholopathy, traumatic brain injury, or stroke.
    Type: Application
    Filed: December 1, 2019
    Publication date: June 18, 2020
    Inventor: Russell Dahl